Changes in biomarkers in equine synovial fluid two weeks after intra-articular hyaluronan treatment: a randomised double-blind clinical trial

Niemelä, Tytti; Tulamo, Riitta‐Mari; Aaltonen, Kaisa; Sankari, Satu; Hielm‐Björkman, Anna

doi:10.1186/s12917-018-1512-2

Cited by 5 publications

(5 citation statements)

References 48 publications

(89 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HA is reported to have an anti-inflammatory effect [16] but IA HA injections have also been documented to induce a transitional IA inflammatory reaction, either a flare with pronounced clinical signs of inflammation and pain [54] or an increase of WBC count in the SF [11]. To our knowledge, only a few studies have explored biomarkers in equine SF after IA HA [3, 11]. As HA is very frequently used in the IA treatment in horses, its mechanism of action warrants further research.…”

Section: Discussionmentioning

confidence: 99%

“…Equine arthritis is commonly treated with intra-articular (IA) corticosteroids and hyaluronan (HA) [10]. However, the response of SF biomarkers after IA HA injection, alone or in combination with other substances, has been examined only in a few equine studies [3, 4, 11]. In human medicine, clinical efficacy of HA has been widely studied [12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the effect of experimentally induced cartilage defect and intra-articular hyaluronan on synovial fluid biomarkers in intercarpal joints of horses

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background Inflammatory and degenerative activity inside the joint can be studied in vivo by analysis of synovial fluid biomarkers. In addition to pro-inflammatory mediators, several anabolic and anti-inflammatory substances are produced during the disease process. They counteract the catabolic effects of the pro-inflammatory cytokines and thus diminish the cartilage damage. The response of synovial fluid biomarkers after intra-articular hyaluronan injection, alone or in combination with other substances, has been examined only in a few equine studies. The effects of hyaluronan on some pro-inflammatory mediators, such as prostaglandin E 2 , have been documented but especially the effects on synovial fluid anti-inflammatory mediators are less studied. In animal models hyaluronan has been demonstrated to reduce pain via protecting nociceptive nerve endings and by blocking pain receptor channels. However, the results obtained for pain-relief of human osteoarthritis are contradictory. The aim of the study was to measure the synovial fluid IL-1ra, PDGF-BB, TGF-β 1 and TNF-α concentrations before and after surgically induced cartilage defect, and following intra-articular hyaluronan injection in horses. Eight Standardbred horses underwent bilateral arthroscopic surgeries of their intercarpal joints under general anaesthesia, and cartilage defect was created on the dorsal edge of the third carpal bone of one randomly selected intercarpal joint of each horse. Five days post-surgery, one randomly selected intercarpal joint was injected intra-articular with 3 mL HA (20 mg/mL). Results Operation type had no significant effect on the synovial fluid IL-1ra, PDGF-BB, TGF-β 1 and TNF-α concentrations but compared with baseline, synovial fluid IL-1ra and TNF-α concentrations increased. Intra-articular hyaluronan had no significant effect on the biomarker concentrations but a trend of mild improvement in the clinical signs of intra-articular inflammation was seen. Conclusions Creation of the cartilage defect and sham-operation lead to an increase of synovial fluid IL-1ra and TNF-α concentrations but changes in concentrations of anabolic growth factors TGF-β 1 and PDGF-BB could not be documented 5 days after the arthroscopy. Intra-articular hyaluronan was well tolerated. Further research is needed to document possible treatment effects of intra-articular hyaluronan on the synovial fluid biomarkers of inflammation and cartilage metabolism.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Evaluation of the effect of experimentally induced cartilage defect and intra-articular hyaluronan on synovial fluid biomarkers in intercarpal joints of horses

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Clinically, OA has no speci c drugs, and is usually limited to palliative measures to relieve pain and relieve symptoms. In small animals and horses, non-steroidal anti-in ammatory drugs (NSAIDs) are important tools for the treatment of OA [4,6,7]. Sulfated glycosaminoglycan or hyaluronic acid injections are often used in horses [7].…”

Section: Paragraphmentioning

confidence: 99%

“…In small animals and horses, non-steroidal anti-in ammatory drugs (NSAIDs) are important tools for the treatment of OA [4,6,7]. Sulfated glycosaminoglycan or hyaluronic acid injections are often used in horses [7]. NSAIDs exert anti-in ammatory effects by self-inhibiting cyclooxygenase (COX-1 and COX-2), which is produced by the breakdown of arachidonic acid due to cell wall damage [8].…”

Section: Paragraphmentioning

confidence: 99%

The Protective Effect of Dietary Administration of Puerarin on Canine Osteoarthritis Model With Anterior Cruciate Ligament Transected

Wen

Song

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundLameness caused by osteoarthritis (OA) is one of the main causes of disability in elderly dogs. Non-steroidal anti-inflammatory drugs (NSAIDs) are important tools in the treatment of canine OA. In recent years, due to the many side effects of NSAIDs, patients cannot tolerate or do not want to take the risk of NSAIDs. People are becoming more and more interested in new treatments for canine OA, and so-called nutritional supplements have emerged. Puerarin has a wide range of pharmacological activities and is often used as a clinical prescription drug and dietary supplement in China. However, the effect of puerarin on canine OA has not been evaluated. Therefore, the purpose of this study is to evaluate the anti-inflammatory and anti-cartilage degradation effects of puerarin in a canine OA model induced by anterior cruciate ligament transection (ACLT), and to detect the serum inflammatory factor interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor α (TNF-α) levels and cartilage degradation biomarker C-terminal telopeptides of collagen type II (CTX-II), cartilage oligomeric matrix protein (COMP) and chondroitin sulfate 846 epitope (CS 846) levels in serum and synovial fluid at different periods of puerarin administration. ResultsEight weeks after the administration, the veterinarian performed clinical and imaging evaluations to comprehensively evaluate the protective effect of puerarin on canine OA. Daily oral administration of 20 mg/kg puerarin can significantly inhibit the expression of IL-1β, IL-6 and TNF-α in serum within 8 weeks (P < 0.05), and its anti-inflammatory effect is similar to oral celecoxib (negative control group). Puerarin has a certain protective effect on articular cartilage and can reduce the level of biomarkers CTX-II, COMP and CS 846 in serum and synovial fluid in the early stage of OA (P < 0.05). In addition, the clinical scores and radiographs scores were significantly reduced after 8 weeks of puerarin treatment (P < 0.05). ConclusionsCanine OA cartilage may be mediated through anti-inflammatory, anti-metabolism and anabolic effects, and strongly down-regulate the inflammatory factors IL-1β, IL-6 and TNF-α and cartilage degradation biomarkers CTX-II, COMP and CS 846 are related, providing a good alternative therapy for OA.

show abstract

“…Hyaluronic acid is synthesized by synoviocytes of the synovial membrane and chondrocytes in the articular cartilage (Caron, 2005). While controversy still exists about the efficacy and duration in horses (Niemelä et al, 2018). HA is recommended for pain relief in human OA (Henrotin et al, 2015).…”

mentioning

confidence: 99%

In vivo joint synovial fluid disposition of a novel sustained‐release formulation of diclofenac and hyaluronic acid in horses

Rhodin

Andersen

Forsström

et al. 2021

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

Osteoarthritis (OA) is the most common type of degenerative joint disease in horses (Goodrich & Nixon, 2006) and humans (Moskowitz, 2009). The disease is a major source of pain, disability and socioeconomic cost worldwide (Woolf & Pfleger, 2003), and results in severe welfare issues and economic losses for humans and for horse-related industries.Osteoarthritis is a complex disease that involves all parts of the joint. It may be caused by a number of different factors, ranging from chronic low-grade micro insults to acute trauma and infection. The involvement of inflammation produced by synovium and chondrocytes is central to the pathogenesis, with inflammatory cytokines, metalloproteases and other inflammatory mediators being present in synovial fluid of patients with OA (2006). The resulting joint pain manifests as lameness (Schlueter & Orth, 2004) and the joint capsule inflammation causes swelling and fibrosis, resulting in additional pain and decreased range of motion of the affected joint. No curative treatments exist for this disease, but early symptomatic treatment can reduce pain and the cartilage-damaging effects of the inflammatory products, and decrease the progression of cartilage destruction and fibrosis of the joint capsule (Goldring & Otero, 2011). In horses, a common treatment regime consists of systemic administration of non-steroidal antiinflammatory drugs (NSAIDs; Goodrich & Nixon, 2006).

show abstract

Changes in biomarkers in equine synovial fluid two weeks after intra-articular hyaluronan treatment: a randomised double-blind clinical trial

Cited by 5 publications

References 48 publications

Evaluation of the effect of experimentally induced cartilage defect and intra-articular hyaluronan on synovial fluid biomarkers in intercarpal joints of horses

Evaluation of the effect of experimentally induced cartilage defect and intra-articular hyaluronan on synovial fluid biomarkers in intercarpal joints of horses

The Protective Effect of Dietary Administration of Puerarin on Canine Osteoarthritis Model With Anterior Cruciate Ligament Transected

In vivo joint synovial fluid disposition of a novel sustained‐release formulation of diclofenac and hyaluronic acid in horses

Contact Info

Product

Resources

About